GlycoMimetics

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

GlycoMimetics reports strong Q4 performance and optimistic clinical advancements

GlycoMimetics delivered a robust performance in Q4 2022, driven by positive clinical outcomes and strategic financial decisions. The company's focus on uproleselan and promising interim utility analysis sets a solid foundation for future growth. While challenges like managing expenses and meeting trial milestones exist, GlycoMimetics is well-positioned to capitalize on opportunities in the biopharmaceutical sector.

GlycoMimetics excels in AML trials, secures funding for future growth

GlycoMimetics showcased strong performance in both clinical trials and financial standing, positioning the company well for future growth.
While challenges in managing expenses and navigating industry complexities exist, opportunities for expansion and innovation through partnerships are promising.

GlycoMimetics advances clinical trials and secures funding until late 2024

GlycoMimetics showcased strong progress in their clinical trials and financial stability during the Q2 2023 Earnings Call. With FDA clearance for Phase III uproleselan study and a cash runway until late 2024, the company is well-positioned for future growth. Challenges include successful trial execution and maintaining financial discipline.

GlycoMimetics progresses in AML trials, eyes positive Phase III results

GlycoMimetics demonstrated strong performance in advancing its clinical pipeline, with a focus on uproleselan in AML.
While facing challenges like delays in studies and increased expenses, the company remains optimistic about future prospects.
Opportunities lie in presenting data at conferences, exploring market expansion, and anticipating positive Phase III results by Q2 2024.

GlycoMimetics reports progress in trials and financial strength for growth

GlycoMimetics' Q4 2023 earnings call showcased positive clinical trial outcomes, strong financial standing, and a strategic focus on addressing unmet medical needs. The company's upcoming milestones, including the Phase III trial results and NDA submission, indicate promising growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022. Cash and cash equivalents at March 31, 2022 were $76.5 million. “During the first quarter, we advanced our transformation from a research company to a commercially-focused organization. Our clinical team continues to collect and confirm data and track events in real time from our Phase 3 trial in the relapsed/refractory patient popul

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1068226. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able t

GlycoMimetics to Report First Quarter Financial Results on April 28, 2022

Investigator-sponsored trials keep piling up.

GlycoMimetics' Uproleselan: Secondary Reasons To Own The Stock

Data delay for AML therapy is most likely due to a positive OS trend.

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the 34th Annual Roth Conference in Laguna Niguel, California, March 14 and 15. Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Zegbeh Jallah, Ph.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.g

GlycoMimetics to Participate at Upcoming Roth Investor Conference

GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q4 2021 Results - Earnings Call Transcript

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the fourth quarter and year ended December 31, 2021. Cash and cash equivalents at December 31, 2021 were $90.3 million. “During 2021, we focused on completing enrollment of our pivotal trial evaluating uproleselan in AML. Towards the end of the year, within two weeks of each other, GlycoMimetics completed enrollment of our Phase 3 trial and the NCI completed enrollment of

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. “Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics,” commented Harout Sem

GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on Thursday, March 3, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4048456. Participants are encouraged to connect 15 minutes in advance of the call to ensure they

GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. “Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial and development activities across multiple launches. He shepherded two AML drugs, Midostaurin and Venetoclax, through late-stage development and approval, uniquely qualifying him to lead the

GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) this week at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta presented two posters providing support for targeting both CXCR4 and E-selectin with GMI-1359, the Company's dual antagonist of CXCR4 and E-selectin, as a novel treatment strategy for patients with AML. “Both posters demonstrate the potential value of blocking extrinsic factors of AML drug resistance in the bone marrow microenvir

Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and the Alliance for Clinical Trials in Oncology, have completed enrollment of 267 patients in the Phase 2 portion of the adaptive Phase 2/3 trial evaluating whether uproleselan improves overall survival in newly diagnosed patients 60 years or older with acute myeloid leukemia (AML)

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Apollomics' Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical tr

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AML

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations. Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team. “Lisa is a seasoned executive

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML. A total of 388 patients across 70 sites in nine countries has now been randomized in the clinical trial, which has a primary endpoint of overall survival, not censored for transplant. GlycoMimetics reiterates its guidance that, based upon current pr

GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)

GlycoMimetics' main AML trial is close to completion of enrollment. Uproleselan Phase 3 trial likely to build on prior positive data.

GlycoMimetics A Buy On Nearing Trial Enrollment Completion

Dunxin Financial Hlds

Fluidigm

Greenpro Capital Corp

Are these on your list of penny stocks to watch today? The post Hot Penny Stocks To Buy Now?

Hot Penny Stocks To Buy Now? 4 To Add To Your List Today

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that two abstracts relating to GMI-1359, the Company's dual antagonist of CXCR4 and E-selectin, have been accepted for poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 11-14, 2021. “The data to be presented at ASH provide further support for targeting both CXCR4 and E-selectin as a novel treatment strategy for patients with AML, particularly

GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Harout Semerjian will present an overview of the company at the upcoming Stifel 2021 Virtual Healthcare Conference on Monday, November 15 and the Jefferies London Healthcare Conference on Wednesday, November 17. Both presentations will be available on the Company's website, under the Investors tab. Details are as follows: Stifel 2020 Virtual Healthcare Conference November 15-17, 202

GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences

GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q3 2021 Results - Earnings Call Transcript

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended September 30, 2021 and highlighted recent events. Cash and cash equivalents at September 30, 2021 were $101.9 million. “I am excited about the strong momentum and opportunities we have in front of us. I am grateful for the dedication and perseverance of our employees and board of directors especially during my CEO transition period,” commented Chief Executive Officer Ha

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Tuesday, November 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 2991493. Participants are encouraged to connect 15 minutes in advance of the call to ensure they are able to conne

GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021

GlycoMimetics Inc (NASDAQ: GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online in the journal BLOOD.  In the manuscript, scientists highlighted an analysis of minimal residual disease (MRD).

GlycoMimetics' Lead Candidate Data Published In An Online Journal

ROCKVILLE, Md.--(BUSINESS WIRE)--Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics' lead investigational drug, were published online September 16, 2021 in the journal BLOOD. In the manuscript, scientists highlight an analysis of minimal residual disease (MRD) and report an MRD negative rate of 69 percent in trial participants with relapsed/refractory acute myeloid leukemia (AML), indicating an enhanced depth of response following addition of uproleselan to s

Efficacy and Safety Data for GlycoMimetics' Lead Investigational Drug Uproleselan Published in BLOOD

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Harout Semerjian will present at the upcoming H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference taking place September 13-15, 2021. The presentation will be available on the company's website at the “Investors” tab for 30 days, beginning Monday, September 13 at 7:00 a.m. EDT. To access the live webcast and subsequent archived recordings for the presentation, p

News for GlycoMimetics Stock (GLYC)